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ANCA-associated vasculitides (AAV) constitute a group of auto-immune diseases 
associated with infl ammation of mainly small blood vessels. In the majority of pa-
tients, antibodies directed against myeloperoxidase (MPO) or proteinase 3 (PR3) are 
present, while some AAV patients are ANCA-negative [1], or have atypical types such 
as bactericidal permeability-increasing protein (BPI)- or human neutrophil elastase 
(HNE)-ANCA [2].
Several subtypes are distinguished based on clinical characteristics. These are gran-
ulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis), microscopic 
polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA, formerly 
Churg-Strauss) and single-organ AAV (most commonly renal-limited AAV) [1]. Re-
nal-limited AAV, or necrotizing and crescentic glomerulonephritis (NCGN), is often 
regarded as a subtype of MPA.
Clinical characteristics of AAV
Although AAV can aff ect any organ, some organs are more frequently aff ected than 
others (Figure 1). The typical characteristics per subtype of AAV are discussed below 
and are summarized in Table 1.
Microscopic polyangiitis (MPA)
MPA is characterized by necrotizing vasculitis with few or no immune deposits (i.e., 
pauci-immune). This disease is not associated with granulomatous infl ammation. The 
most common manifestations are necrotizing crescentic glomerulonephritis (NCGN) 
and pulmonary capillaritis presenting as hemoptysis, dyspnea or even respiratory fail-
ure [1].  Other common manifestations are skin symptoms, most commonly purpura, 
and mononeuritis multiplex.
Granulomatosis with polyangiitis (GPA)
GPA is characterized by neutrophil-rich granulomatous infl ammation of the upper 
(e.g., nasal crusting, epistaxis, hearing loss, subglottic stenosis) and lower respiratory 
tract (e.g., pulmonary nodules or cavities). NCGN is also common. Other frequent 
manifestations include ocular vasculitis (e.g., conjunctivitis, (epi-)scleritis), purpura, 
mononeuritis multiplex and pulmonary capillaritis with hemorrhage. Limited forms 
of GPA exist with only involvement of the eyes or the upper or lower airways. Limited 
GPA usually requires less intensive treatment [1]. 
Eosinophilic granulomatosis with polyangiitis (EGPA)
EGPA is characterized by eosinophil-rich granulomatous infl ammation of the upper 
and lower respiratory tract. The most characteristic manifestations are eosinophilia, 
asthma and nasal polyps. Other common manifestations include eosinophil-rich 
infl ammation of the myocardium and gastrointestinal tract. Most patients are AN-
CA-negative. ANCA-positive EGPA patients more frequently have vasculitis symptoms 
such as alveolar hemorrhage, glomerulonephritis and peripheral neuropathy, while 
ANCA-negative patients have a higher risk of cardiovascular involvement and eosino-
philic tissue infi ltration [3]. EGPA also has a limited form with only involvement of the 
upper or lower respiratory tract [1]. 
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Figure 1. Possible symptoms of ANCA-associated vasculitis. 
Reproduced with permission from Janneke Tuin, MD, PhD.
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ANCA specifi city to categorize patients
Increasing evidence suggests that ANCA specifi city may be a better way of classifying 
AAV patients than the previously mentioned clinical subtypes [4]. In a genome-wide as-
sociation study (GWAS) investigating the genetic basis for AAV, ANCA specifi city showed 
stronger genetic associations than clinical subtype [5]. It is also a better predictor of 
relapse than clinical subtype, with PR3-ANCA positive patients having a higher risk of dis-
ease relapse [6,7]. Some studies suggest that MPO-ANCA positive patients have a higher 
risk of mortality and end-stage renal disease [8,9], while other studies show no predictive 
value of ANCA specifi city for either outcome [6].
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Table 1. Clinical phenotypes of ANCA-associated vasculitis.
EGPA eosinophilic granulomatosis with polyangiitis; GPA granulomatosis with polyangiitis; 
MPA microscopic polyangiitis; NCGN necrotizing and crescentic glomerulonephritis. MPA 
includes patients with renal-limited ANCA-associated vasculitis.























































Epidemiology and risk factors of AAV
The annual incidence of AAV is low. In Europe, it is estimated to be 13-20/million. The 
prevalence of AAV is approximately 46-184/million. Slightly more males than females are 
affected. While it can occur at any age, the highest incidence of AAV is in the 6th and 7th 
decades [10].
Geographic differences exist regarding the distribution of ANCA specificities. MPO-AN-
CA is more common in Japan and China, while PR3-ANCA is more common in Northern 
Europe, the Middle East and India. MPO-ANCA and PR3-ANCA occur in similar frequency 
in Caucasian Americans and Southern Europeans [11]. 
Genetic and environmental factors both have a potential role in AAV pathogenesis. In 
the previously mentioned GWAS, genetic associations were found with major-histo-
compatibility complex (MHC) and non-MHC loci, which differed depending on ANCA 
specificity (e.g., HLA-DP and genes encoding α1-antitrypsin (SERPINA1) and proteinase 
3 (PRTN3) for PR3-ANCA; HLA-DQ for MPO-ANCA). Smaller associations were found with 
factors such as interleukin-10 (IL10) and cytotoxic T-lymphocyte-associated protein 4 
(CTLA4). All factors make only a small contribution to disease risk, but may help identify 
targets for therapy [5]. 
Several findings suggest a role for the environment in AAV pathogenesis. First, some 
studies suggest a role for infections in AAV pathogenesis. In particular, Staphylococcus 
aureus has been implied to play a role in the pathogenesis of GPA [12]. This is supported 
by the effectiveness of the antimicrobial drug co-trimoxazole for maintenance of remis-
sion in GPA [13]. Second, GPA and EGPA incidence increase with higher geographic alti-
tudes and lower ambient UV exposure; this association was not found for MPA patients 
[14]. Last, silica exposure has been suggested as a risk factor for AAV [15].
In conclusion, several genetic and environmental factors make a limited contribution to 
risk of developing AAV. In most cases, the specific cause of disease is unknown. Impor-
tantly, AAV is not a genetic disease in the narrow sense, as genetic factors alone are not 
sufficient to trigger disease. 
Current treatment of AAV
History of AAV treatment
Over the past decades, AAV has developed from a deadly disease with a first-year mor-
tality rate of over 80% to a chronic relapsing-remitting disease with a remission rate of 
over 90% and a 5-year survival rate of over 75% [8]. This results in a large part from the 
introduction of immunosuppressive therapy with glucocorticoids and oral cyclophos-
phamide in the 1960s [16,17]. 
Unfortunately, a high cumulative dose of cyclophosphamide is associated with severe 
adverse effects such as hemorrhagic cystitis, neutropenia, infections and (hematological 
and urinary) malignancies [18]. The CYCAZAREM trial, published in 2003, showed that 
cyclophosphamide therapy can be safely shortened by switching to the less toxic drug 
azathioprine after attaining disease remission for three consecutive months [19]. In a fur-
ther attempt to reduce cumulative cyclophosphamide exposure, the CYCLOPS trial was 
conducted, comparing oral cyclophosphamide to pulsed intravenous cyclophospha-
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mide with lower cumulative cyclophosphamide dose. The results of this study showed 
that pulsed intravenous cyclophosphamide was as eff ective as oral cyclophosphamide 
for inducing remission [20], but was associated with a higher long-term risk of relapse 
[21]. 
In a search for safer alternatives to cyclophosphamide, the RAVE and RITUXVAS studies 
were conducted and published in 2010. These studies showed that the anti-CD20 
monoclonal antibody rituximab had non-inferior effi  cacy compared to cyclophospha-
mide [22,23]. In the short-term results of the RAVE trial, rituximab was even superior 
to cyclophosphamide for treatment of relapsing patients [22]. On the other hand, 
rituximab was no longer superior at long-term follow-up, although this might be due 
to a lack of maintenance therapy in the rituximab group [24]. Also, rituximab treatment 
was not associated with fewer (infectious) adverse events [22,23].
Induction therapy
The EULAR/ERA-EDTA recommendations published in 2016 make a distinction be-
tween organ- or life-threatening disease and non-organ threatening disease [25]. For 
organ- or life-threatening disease, cyclophosphamide or rituximab are combined with 
high-dose glucocorticoids, which are slowly tapered starting after six weeks. In non-or-
gan threatening disease, treatment with less toxic drugs such as methotrexate or 
mycophenolate mofetil may be given together with glucocorticoids. In patients with 
rapidly progressive renal failure (serum creatinine >500 μmol/l and/or dialysis depen-
dency) or diff use alveolar hemorrhage, additional treatment with plasma exchange 
(PLEX) is advised [25]. Although PLEX for severe renal AAV showed short-term effi  cacy 
in the MEPEX trial [26], long-term results showed no reduction of end-stage renal 
disease or mortality [27]. In a presentation at the 55th ERA-EDTA congress in 2018, 
preliminary results from the completed PEXIVAS trial (ISRCTN07757494; clinicaltrials.
gov NCT00987389), that enrolled over 700 patients with a follow-up of up to 7 years, 
suggested no eff ect of PLEX.
Maintenance therapy
After three months of stable remission on induction therapy, patients switch to a 
maintenance therapy using azathioprine, rituximab, methotrexate or mycophenolate 
mofetil combined with low-dose glucocorticoids [25]. Based on the results of the 
IMPROVE trial, azathioprine is preferred over mycophenolate mofetil for maintenance 
therapy [28]. Methotrexate is another eff ective drug for maintenance of remission [29] 
and is seen as an equivalent option to azathioprine [25]. The results of the MAINRIT-
SAN trial, conducted by the French Vasculitis Study Group, suggest that rituximab may 
be superior to azathioprine as remission maintenance therapy following induction 
therapy of pulsed intravenous cyclophosphamide and glucocorticoids, even up to 
60 months of follow-up [30,31]. However, long-term toxic eff ects of rituximab use are 
largely unknown. An important long-term adverse eff ect is hypogammaglobulinemia, 
which results in a higher risk of severe infections [32]. 
The subsequently performed MAINRITSAN2 trial indicated that exposure to rituximab 
maintenance therapy could be reduced safely by 1-3 infusions (out of 5) when only 
infusing rituximab upon a return of CD19+ B lymphocytes or a rise in ANCA titer [33].
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General consensus is that maintenance therapy should be continued for 24 months [25]. 
Recent data on the optimal duration is contradictory. One study concludes that extending 
maintenance therapy with azathioprine and low-dose prednisolone to 48 months reduc-
es relapse risk and increases renal survival [34], while another suggests that continuing 
for more than 18 months does not further reduce relapse risk [35]. These different results 
might be explained by the duration of low-dose prednisolone therapy, as longer courses 
of glucocorticoids likely protect against relapse [36]. This should be weighed against the 
cumulative adverse effects of glucocorticoids [37].
Treatment of EGPA patients
Because of the different clinical picture of EGPA compared to GPA and MPA patients [1], 
especially due to frequent exacerbations of asthma and rhinosinusitis, treatment in EGPA 
differs in some aspects. Patients with life- and/or organ-threatening disease are treated 
similarly to other types of AAV, with a lower priority to rituximab because of limited expe-
rience with the drug in EGPA [38]. Patients without these manifestations may be treated 
with glucocorticoid monotherapy [38], although more recent recommendations advise 
full induction and maintenance therapy in all EGPA patients [25]. Besides vasculitis treat-
ment, EGPA patients require therapy for asthma and rhinosinusitis [3]. 
New developments in treatment
Recently, research focus has shifted towards precision medicine, specifically targeting 
pathophysiologic pathways in AAV [4]. This approach aims to reduce cumulative exposure 
to the currently used drugs and their toxic effects by (partly) replacing them with drugs 
targeting specific inflammatory pathways involved in AAV pathogenesis. For example, the 
CLEAR trial investigates the complement C5a receptor inhibitor avacopan as a possible 
replacement for glucocorticoids [39]. Also, in a randomized clinical trial, adding anti-inter-
leukin-5 monoclonal antibody mepolizumab to standard therapy in patients with relaps-
ing of refractory EGPA increased duration of remission and resulted in a modest reduction 
of required prednisolone dose [40].
Current outcomes in AAV
Relapse
Despite effective treatment for AAV, still many patients (35% within 5 years [41]; 25-59% 
depending on the number of risk factors [7]) experience disease relapses that result in 
damage and require renewed immunosuppressive therapy. Several predictors of relapse 
have been identified, including PR3-ANCA positivity, pulmonary and cardiovascular in-
volvement of AAV.[7,42] A higher serum creatinine at baseline was found to be protective 
against relapse [7].
Mortality
As mentioned previously, survival of AAV has drastically improved after the introduction 
of immunosuppressive therapy. Still, AAV patients have a reduced overall survival com-
pared to the general population [8]. In untreated AAV, disease activity was the main cause 
of death. 
Nowadays, adverse effects of therapy, in particular infections, account for 60% of deaths 
in the first year. Approximately 15-20% of early deaths are still caused by active vasculitis 
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[8,43]. During long-term follow-up, causes of death are at least partly treatment-related, 
namely cardiovascular disease (26%), malignancy (22%) and infection (20%) [8]. Impor-
tantly, renal function after induction of remission is a main predictor of both adverse 
events and overall survival [8,43]. This stresses the importance of limiting both disease 
activity and treatment toxicity, which results in a delicate balance.
Challenges in AAV treatment
Now that disease activity can be eff ectively treated and survival has drastically improved, 
research focus shifts to new challenges in AAV treatment. One of them is accumulation 
of damage from disease activity and treatment. Another is a reduced quality of life de-
spite successful treatment of disease activity.
Damage from disease and treatment
Over the course of their disease, AAV patients accumulate damage from disease activity 
and treatment. At long-term follow-up, approximately 90% of patients will have some 
form of damage, with 34% of patients having at least fi ve items from the Vasculitis 
Damage Index (VDI) [44]. Of note, a major limitation of the VDI is that it is a cumulative 
scoring system taking into account any damage that exists for at least three consecutive 
months. It does not make a distinction between temporary and permanent damage [45]. 
Frequent disease-related damage items for MPA/MPO-ANCA patients include proteinuria 
and reduced renal function (GFR <50mL/min), while frequent damage items for GPA/
PR3-ANCA patients include hearing loss and nasal crusting [44]. At long-term follow-up, 
approximately 67% of patients have VDI items that are potentially treatment-related, 
most commonly hypertension, osteoporosis, malignancy and diabetes [44]. Older age, 
elevated serum creatinine, higher disease activity score, higher number of relapses and 
higher cumulative glucocorticoid use are all independent risk factors for increased dam-
age [37].
Quality of life
Quality of life (QoL), especially physical QoL, is reduced in AAV [46,47]. This is true even 
after successful achievement of remission. Several predictors of QoL have been identi-
fi ed. Predictors of poor physical QoL include older age, prednisolone use and nervous 
system involvement [46,48]. Predictors of poor mental QoL include fatigue and psycho-
logical variables such as depression and anxiety [46,49]. The relation of QoL with damage 
as measured by the VDI is unclear, as some studies report associations of VDI score with 
physical QoL [50,51], while others did not fi nd any association between the outcomes 
[46,47,52].
Respiratory and quadriceps muscle strengths are reduced in AAV. Both seem to contrib-
ute to a reduced exercise capacity. Leg fatigue is the main reason reported by patients 
to prematurely stop an exercise. Reduced exercise tolerance, in turn, contributes to poor 
physical QoL [53]. Based on this data and the reported eff ects of interventions in condi-
tions such as chronic obstructive pulmonary disease and rheumatoid arthritis [54,55], 
exercise training might be benefi cial for QoL in AAV.
AAV patients report increased fatigue compared to controls. The extent of fatigue is as-
sociated with damage from disease and treatment [56]. Fatigue is negatively correlated 
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to QoL [49,56]. Interestingly, the lower measured quadriceps force in AAV seems to result 
from higher perceived exertion rather than reduced muscle mass or function [56]. The 
most important predictors of fatigue are depression, anxiety, pain and sleep disturbance 
[49,56]. These results point out that a rehabilitation program for AAV patients should 
address psychosocial factors in addition to exercise capacity. The recently developed 
patient-reported outcomes questionnaire (AAV-PRO) may assist in monitoring such a 
program [57].
Aims of this thesis
In order to improve the balance between inflammation and treatment toxicity in AAV 
and give treatment tailored to the individual, determinants of efficacy and toxicity first 
have to be identified. The aim of this thesis is therefore to identify predictors of treat-
ment efficacy and toxicity that can be used to optimize therapy of AAV.
In the first part, we investigate genetic factors that may predict efficacy and toxicity 
of AAV treatment. In Chapter 2, we review the literature for genetic polymorphisms 
associated with outcomes of current treatment in AAV. In Chapter 3, we investigate 
genetic variants and activity levels of the enzyme thiopurine methyltransferase (TPMT) 
in relation to efficacy and toxicity of azathioprine maintenance therapy. In Chapter 4, 
we investigate whether haplotypes of the glucocorticoid receptor (GR) and a single-nu-
cleotide polymorphism of 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) affect 
disease outcomes in AAV patients treated with standard immunosuppressive therapy. 
Though we report some interesting associations of gene variants with clinical outcomes, 
we conclude that clinical application of these variants is still several steps away.
The second part of this thesis focuses on characterization of treatment outcomes in AAV. 
In Chapter 5, we investigate differences in clinical presentation and outcomes of AAV 
between Brazil, China and the Netherlands, and whether these may (partly) be explained 
by differences in ANCA-specificity. In Chapter 6, we discuss the azathioprine hyper-
sensitivity syndrome and its characteristics in an observational cohort of AAV patients. 
In Chapter 7, we investigate whether steroid myopathy and reduced physical activity 
might be part of the explanation for reduced physical quality of life in AAV. With this part, 
we hope to raise awareness of differences in treatment response between countries, the 
high frequency of azathioprine hypersensitivity and the associations of reduced muscle 
strength and physical activity with reduced quality of life in AAV.
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